Registration for a live webinar on 'Chronic inflammation, immune cell trafficking and anti-trafficking agents' is now open.See webinar details
Human tumor antigens as therapeutic targets of cancer
Published on August 31, 2015 31 min
Other Talks in the Series: Immunotherapy of Cancer
Immunotherapy in neuroendocrine tumors 2 - role of immunotherapy
- Dr. Nitya Raj
- Memorial Sloan Kettering Cancer Center, USA
Immune checkpoint blockade in CNS tumors
- Dr. Md. David A. Reardon
- Center for Neuro-Oncology Dana-Farber Cancer Institute, USA
Hi. My name is Ben Seon. Today I'm going to talk about human tumor antigens as the therapeutic target of cancer.
Tumor cells express many different type of antigens. And I listed some of these antigens that potentially can be used for targeting purposes. First, products of oncogenes and the tumor suppressor gene products and cancer-Testis antigen, oncofetal antigen, differentiation antigen, and angiogensesis associated antigen, and immune checkpoint molecule. Traditionally, immune checkpoint molecule is not included in the tumor antigens. But due to recent successes by James Allison and his group, and also others, for targeting this molecule, I include it here. However, I'm not going to talk about this one because other speakers will discuss this topic in this series of lectures.
Druker and his associates targeted and treated, CML, chronic myeloid leukemia patients, who express BCR-ABL tyrosine kinase inhibitors. This is a fusion protein using a specific inhibitor, Gleevec. Now the result is striking. In dose escalation studies, at highest dose, there is a 300 to 1,000 milligram per day. 53 out of 54 patient responded completely. A complete response of 98%. So this is an amazing result.